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Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic
hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines
to increase response rates and to reduce side effects and costs. However, it is unknown
whether individualization was adopted in routine daily practice and whether it translated into
improved outcomes.
Methods
From a large noninterventional cohort study, clinical and virologic response data of 10,262
HCV patients who received peginterferon alfa-2a and ribavirin between 2003-2007 and
2008-2011 were analyzed. To account for treatment individualization, a matched-pair analy-
sis (2,997 matched pairs) was performed. Variation in treatment duration and dosing of riba-
virin were analyzed as indicators for individualization.
Results
Sustained virological response (SVR) rates were similar between 2003-2007 and 2008-
2011 (62.0% vs. 63.7%). Patients with comorbidities were more abundant in the later
period, (44.3% vs. 57.1%). The subsequent matched-pair analysis demonstrated higher
SVR rates in the 2008-2011 period (64.3%) than in the 2003-2007 period (61.2%, p=0.008).
More patients received abbreviated or extended treatment regimens in the later than the
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earlier period as an indicator of treatment individualization. To the same end, ribavirin doses
were higher in the later period (12.6 versus 11.6 mg/kg/day). Factors independently associ-
ated with SVR included HCV genotype, low baseline viral load, younger age, route of infec-
tion, absence of concomitant diseases, lower APRI score, normal gamma-GT, higher
ribavirin doses, no substitution for drug abuse, treatment duration, and treatment in the
2008-2011 period.
Conclusions
Treatment individualization with peginterferon alfa and ribavirin was implemented in daily
routine between 2003-2007 and 2008-2011, SVR rates improved in the same period. These
findings may be most relevant in resource-limited settings.
Introduction
Chronic hepatitis C virus infection (CHC) causes progressive liver disease. The risk of develop-
ing liver cirrhosis is estimated at 5–30% after 20–30 years of infection [1,2]. A sustained viro-
logic response (SVR) after a course of antiviral therapy is generally accepted as a surrogate
marker for cure. SVR prevents the progression of liver disease, reduces the risk of HCC,
improves liver-related and overall mortality, and eliminates the risk to spread HCV infection
[3,4].
Prior to licensing of the first direct-acting antiviral agents (DAA) in 2011, treatment with
pegylated interferon (pegIFN) alfa-2a or alfa-2b and ribavirin was the standard-of-care for
patients with CHC for nearly one decade [5]. According to initial treatment algorithms,
patients infected with HCV genotype 1 or 4 were treated for 48 weeks and those infected with
HCV genotype 2 or 3 were treated for 24 weeks, resulting in SVR rates ranging from 42% to
52% and 76% to 82%, respectively [6–9]. More recently, host and viral factors associated with
treatment response were identified and were used to tailor treatment according to a patient’s
individual profile. Host factors include age, gender, ethnicity, weight, associated liver disease,
insulin resistance, adherence to therapy, and genetic polymorphisms such as the IL28B geno-
type [10,11]. Viral factors include the HCV genotype, the pretreatment HCV RNA level and
the on-treatment virologic response at weeks 4 (RVR, rapid virological response) and 12 (EVR,
early virological response) [12].
Several randomized controlled trials were conducted in the past decade to individualize
treatment algorithms for chronic hepatitis C in particular with regard to treatment duration
[12]. Abbreviated treatment regimens should ideally reduce the rate of adverse side effects and
costs without compromising antiviral efficacy. Extended treatment durations aim at increasing
SVR rates in selected patients who are slow responders to treatment [13–15]. Indeed, patients
with genotype 1 and low baseline viral load who achieve RVR can shorten treatment to 24
weeks without reducing efficacy [16–18]. Treatment extension to 72 weeks in genotype 1
patients is considered in subgroups of patients without complete EVR [19–21]. Selected geno-
type 2 or 3 patients who achieve RVR and who exhibit additional favorable prognostic host fac-
tors may likewise be treated for shorter durations (12–16 weeks) [22–25]. Genotype 2 or 3
patients who fail to eliminate HCV RNA by week 4 may instead benefit from extending treat-
ment duration to 48 weeks [26].
Dosing of ribavirin is another important factor for individualization as higher doses
improve SVR rates and reduce virologic relapse rates (27, 28). Administration of weight-based
Real-World Treatment Individualization in CHC
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ribavirin (ranging from 800 mg to 1400 mg per day in genotype 1 patients) is superior to fixed
dosed ribavirin (800 mg). Higher doses of up to 15 mg per kg are more effective but are also
associated with higher rates of adverse effects (29, 30).
Noninterventional cohort studies fill the gap between highly controlled randomized trials
and the reality of everyday practice. They usually enroll a broader population of patients than
randomized controlled trials, including those who are older and have comorbidities. Further-
more, they provide information about adherence of physicians to practice guidelines.
Results of several noninterventional cohort studies demonstrated that treatment efficacy in
everyday practice is generally comparable to clinical trials of HCV treatment [27, 28]. However,
it is unknown whether individualization of treatment regimens has been adopted by physicians
and has led to improved SVR rates in daily practice [29].
Patients and Methods
This analysis derives from three consecutive German multicenter noninterventional studies in
patients with CHC receiving pegIFN alfa-2a and ribavirin, involving 432 physicians/institu-
tions throughout Germany (369 in office based practice and 63 in hospital settings).
Patients were included in the first study fromMarch 2003 to February 2006. The second
study recruited patients fromMarch 2006 to December 2008 and the third study started in Jan-
uary 2009. The last patient entered this study in October 2011, and the last data entry was in
December 2013. A total of 16,359 patients were included in these noninterventional studies.
The present analysis was conducted in January 2013 with 12,081 previously untreated patients
without HIV or HBV coinfection and without previous solid organ transplantation of whom
documentation was complete.
The recommended treatment duration for patients with genotypes 2 and 3 infection was 24
weeks until 2010, when German guidelines [30] were revised and recommended 16 weeks of
treatment in patients who achieved RVR and 48 weeks of treatment in patients who did not
achieve RVR. For genotype 1, 4, 5, and 6 infections the recommended treatment duration was
48 weeks initially. In 2007 abbreviation of the treatment duration to 24 weeks was approved for
pegIFN alfa-2a for patients with genotype 1 infection and low baseline viremia ( 800.000 IE/
ml) or with genotype 4 who achieved RVR. The treatment period was followed by an observa-
tional period of 24 weeks. The recommended dosage of pegIFN alfa-2a was 180 μg once weekly
in combination with ribavirin according to the SPCs of manufacturers.
Inclusion criteria in the present cohort were age of at least 18 years, quantifiable HCV RNA
(baseline HCV-RNA was not available in 439 out of 16,359 patients), compensated liver dis-
ease, and written informed consent. RVR was defined as HCV RNA negativity at week 4 with a
window from day 23–33 of treatment. SVR was defined as non-detectable HCV RNA 24 weeks
after completion of the treatment period. Virological failure was defined as<2 log decline of
HCV RNA from baseline at week 12.
Data were obtained on structured questionnaires. Screening data included demographic
data, history of HCV infection, and concomitant diseases. On-treatment information about
virological response and drug safety was collected using online data entry. The studies repre-
sent an unselected cohort in a real-life setting including a significant fraction of all patients
treated for chronic hepatitis C monoinfection in Germany.
Because of limited numbers of liver biopsies, the degree of liver fibrosis was estimated by APRI
(aspartate aminotransferase—platelet ratio index) using pre-treatment laboratory data [31].
For comparison of the evolvement of treatment outcomes two periods were compared: an
earlier period before the recommendation of treatment individualization (2003–2007) and a
later period after recommendation of treatment individualization (2008–2011).
Real-World Treatment Individualization in CHC
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The weight-based ribavirin dose was calculated as follows: cumulative ribavirin dose divided
by the number of days of treatment and the body weight of the patient per kilogram.
Ethics statement
Studies were announced to health authorities and ethical committees according to German
drug law. The study was approved by health authorities and the ethical committee Ethik-Kom-
mission der Ärztekammer Westfalen-Lippe, Münster, Germany. This study and all related
studies for this drug are registered in the national register for non-interventional studies at vfa
(Verband Forschender Arzneimittelhersteller e.V., Berlin, Germany). Written informed con-
sent was obtained from all patients.
Study cohort
The entire cohort consists of 16,359 HCV patients who received pegIFN alfa-2a and ribavirin
between 2003–2007 (n = 8,563) and 2008–2011 (n = 7,796).
Intention-to-treat cohort (ITT). 2,058 patients were excluded because they were not
treatment naïve, 803 were excluded due to HIV co-infection, 748 were excluded due to HBV
co-infection, and 16 patients were excluded because they had previously received an organ
transplant. The entire naïve ITT cohort therefore consisted of 12.801 treatment-naïve patients
infected with HCV, 6,643 of whom were treated in the 2003–2007 period while 6,158 patients
were treated in the 2008–2011 period.
Per protocol cohort (PP). The per protocol cohort consisted of 10,262 patients, excluding
patients whose treatment was discontinued for other reasons than poor tolerability, concomi-
tant diseases, or virological non-response, i.e. mainly due to non-compliance or patients’
request as well as loss to follow-up. 5,386 patients from the PP cohort were treated in the 2003–
2007 period, and 4,876 patients were treated in the 2008–2011 period.
Matched-pairs analysis from the PP cohort (MP-PP). To account for differences regard-
ing patient characteristics and important predictive baseline factors in the earlier and later
treatment period, a matched-pairs analysis was performed for the PP cohort. Matched pairs
were formed by matching age within 5 years, the HCV genotype, baseline viral load (low or
high viral load with best cut-off of 470.000 IE/ml, see below), APRI-Score (< 0.5, 0.5–< =
1.5, 1.5–< = 2,> 2), possible route of infection (intravenous drug abuse, blood or blood prod-
ucts, other/unknown), presence of concomitant diseases, baseline gamma-GT (within normal
range (male< 66 U/l; female:< 39 U/l) vs. elevated), and substitution for intravenous drug
abuse. A total of 2,997 matched pairs (PP MP) were created with the above mentioned match-
ing criteria.
Matched-pairs analysis from PP completer cohort (MP-PP completer). In order to
determine whether treatment individualization was implemented in the later period, patients
who discontinued treatment before the planned treatment termination were excluded from the
PP matched-pairs completer cohort. This data set should be better suited to analyze whether
treatment individualization did indeed take place in the later period as factors confounding the
treatment duration were eliminated. A total of 2,439 of the patients included in this cohort
were treated in the 2003–2007 period, and 2,475 patients were treated in the 2008–2011 period.
Statistical Analysis. The statistical analysis was descriptive to reflect the clinical routine as
intended by the clinicians. Summary statistics (mean, median, standard deviation, 25th percen-
tile, 75th percentile, minimum, maximum, number of values) or frequencies and proportions
were assessed depending on the scale level of the data.
For the continuous predictive factors age and baseline HCV RNA receiver operating charac-
teristic (ROC) analyses estimated the best cut-off point for SVR. The cut-off points found for
Real-World Treatment Individualization in CHC
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the continuous variables were used to generate the corresponding categorial variables. The cut-
off point for age was determined as< 45 / 45 years. The cut-off for baseline viral load was
determined as< 470.000 IU/ml versus / 470.000 IU/ml. Route of infection was categorized
as transfusion/blood products, illicit drugs, or other/unkown. Further categorical variables
were gender, concomitant disease (yes/no), substitution for opioid abuse (yes/no), elevated
gamma-GT (yes/no), and APRI score (< 0.5; 0.5– 1.5; 1.5–2;> 2). An univariate analysis
of these factors was performed initially followed by multivariate analysis of all factors showing
significant associations in the univariate analysis (p0.05).
Differences in baseline clinical characteristics and safety and efficacy data were compared
using univariate and multiple logistic regression analyses including odds ratio and 95% confi-
dence interval.
All statistical analyses were based on 2-sided hypothesis tests. Analyses were carried out
using SPSS 12.0.2 (SPSS Inc., Chicago, Illinois, USA), Testimate, version 6.4.27 (Institute for
Data Analysis and Study Planning, Gauting/Munich, Germany) and Matched Version 1.1.
(Institut für Medizinische Statistik und Dokumentation, Erlangen).
Results
Characterization of the study cohort
Between 2003 and 2011 a total of 16,359 patients were included into the study, 8,563 patients
were treated in the 2003–2007 period, and 7,796 patients were treated in the 2008 to 2011
period (Fig 1). 9,609 patients were infected with HCV genotype 1, 1,116 and 4,964 patients
were infected with HCV genotypes 2 and 3, respectively, and 605 patients were infected with
HCV genotype 4. Few patients were infected with HCV genotypes 5 (n = 30) or 6 (n = 35).
63.5% of patients were male, and the median age was 42 years. 84.1% of patients were of Cauca-
sian ethnicity. The possible route of infection reported most frequently by the physician was
intravenous drug abuse in 42.3% of patients, followed by treatment with blood or blood prod-
ucts in 13.7% of patients. The possible route of infection was unknown/other in 44.0% of
patients. 56.7% of patients had concomitant diseases. 12.8% suffered from psychiatric disease,
8.4% suffered from cardiovascular disease, and 4.0% and 3.0% suffered from diabetes and pul-
monary disease, respectively. 22.8% of patients self-reported former or current intravenous
drug abuse and 12.1% of patients were on opioid substitution treatment.
In the ITT cohort SVR rates were 50.3% in the 2003–2007 period and 50.5% in the 2008–
2011 period.
Further analyses were performed in the PP cohort. SVR rates were also not statistically dif-
ferent in the PP cohort between the early and late treatment period (62.0% versus 63.7%). Like-
wise SVR rates did not differ for patients infected with HCV genotype 1 (52.0% vs. 55.6%),
genotype 2 (73.9% vs. 76.2%), genotype 3 (79.3% vs. 77.6%), or genotype 4 (56.9% vs. 54.4%).
The percentage of relapsers (13.6% vs. 12.9%) and virologic non-responders (24.4% vs. 23.3%)
also did not differ.
Treatment was terminated due to virologic non-response in 11.2% of patients in the earlier
treatment period and in 13.1% of patients in the later treatment period and due to poor tolera-
bility in 6.3% and 4.0%, respectively. Patients terminating the treatment for other reasons
(incompliance, poor tolerability, non-compliance, patients’ request, or loss to follow-up) were
excluded form the PP cohort but are shown for the ITT cohort (Table 1).
A significantly higher proportion of patients in the later treatment period had comorbidities
than in the earlier period (Table 1). Therefore, a matched pair analysis was performed to con-
trol for bias related to this observation.
Real-World Treatment Individualization in CHC
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Matched-pair analysis
A total of 2,997 matched pairs remained for the MP-PP cohort. The majority of patients was
infected with genotype 1 (n = 1,946), followed by patients infected with genotype 3 (n = 861).
Lesser numbers of patients were infected with genotypes 2 (n = 147) and genotype 4 (n = 43).
Demographic data are shown in Table 2.
Fig 1. Patient disposition. APRI, aspartate aminotransferase (AST) platelet ratio index; GGT, gamma-
glutamyl transferase; HBV, hepatitis B virus; HIV, human immunodeficiency virus; ITT, intent to treat; MP,
matched pairs; PP, per protocol
doi:10.1371/journal.pone.0134839.g001
Real-World Treatment Individualization in CHC
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Table 1. Baseline demographics, virological responses, treatment discontinuations as well as treatment duration andmean ribavirin dose in the
two treatment periods 2003–2007 and 2008–2011 in the ITT and PP cohorts.
ITT PP
2003–2007 2008–2011 p-value total 2003–2007 2008–2011 p-value total
Number of patients (n) 6643 6158 12801 5386 4876 10262
Age (Yrs, mean) 41.6 41.8 n.s. 41.7 42.5 42.7 n.s. 42.6
Gender (male, %) 60.4 63.3 ** 61.8 58.5 60.8 ** 59.6
BMI (kg/m², mean) 25.1 25.5 *** 25.3 25.2 25.6 *** 25.4
Ethnicity, Caucasian (%; adjusted by unknown)† 74.6 96.2 * 85.0 73.6 96.0 n.s. 84.3
APRI Score (%) n.s. n.s.
< 0.5 44.5 44.5 44.5 44.3 44.0 44.2
0.5-< = 1.5 41.7 42.0 41.8 41.8 42.2 42.0
1.5-< = 2 4.8 4.7 4.7 4.8 4.8 4.8
>2 8.9 8.9 8.9 9.0 9.0 9.0
Baseline GGT (IU/ml, mean) 80 93 ** 86 81 90 * 85
Route of infection (%): *** ***
Transfusion/blood products 16.8 10.5 13.8 18.5 11.8 15.3
Intravenous drug abuse 40.7 45.9 43.2 36.7 42.0 39.2
Other / unknown 42.5 43.7 43.1 44.8 46.2 45.4
Concomitant diseases (%): 44.3 58.0 *** 50.9 44.3 57.1 *** 50.4
Psychiatric 8.9 14.6 *** 11.6 8.5 14.4 *** 11.3
Cardiovascular 7.6 8.5 n.s. 8.0 8.5 9.4 n.s. 8.9
Diabetes 3.5 3.8 n.s. 3.6 3.8 4.1 n.s. 3.9
Pulmonary 2.6 3.2 n.s. 2.9 2.7 3.5 * 3.1
Former iv drug abuse 15.1 30.4 *** 22.5 13.5 27.1 *** 20.0
Opioid substitution treatment 7.4 17.4 *** 12.2 6.4 16.1 *** 11.0
Genotype (%): ** n.s.
1 57.1 57.1 57.1 59.2 59.0 59.2
2 8.0 6.6 7.3 8.1 6.9 7.5
3 31.7 32.6 32.1 29.3 30.5 29.8
4 2.7 3.4 3.0 2.8 3.3 3.1
5 0.2 0.1 0.2 0.3 0.1 0.2
6 0.3 0.2 0.2 0.3 0.2 0.2
High baseline viral load (> 470.000 IU/ml, %) 52.9 55.8 ** 54.4 52.8 56.7 *** 54.7
RVR (%) 43.7 43.0 n.s. 43.3 43.6 41.2 n.s. 42.1
SVR total (%) 50.3 50.5 n.s. 50.4 62.0 63.7 n.s. 62.8
SVR genotype 1 (%) 43.7 45.5 n.s. 44.6 52.0 55.6 ** 53.7
SVR genotype 2 (%) 60.8 62.9 n.s. 61.7 73.9 76.2 n.s. 74.9
SVR genotype 3 (%) 59.4 57.4 n.s. 58.4 79.3 77.6 n.s. 78.5
SVR genotype 4 (%) 48.3 41.8 n.s. 44.8 56.9 54.4 n.s. 55.6
SVR genotype 5 (%) 62.5 62.5 n.s. 62.5 66.7 71.4 n.s. 68.2
SVR genotype 6 (%) 64.7 70.0 n.s. 66.7 78.6 77.8 n.s. 78.3
Treatment discontinuation (%)‡ 23.1 27.2 *** 25.1 17.4 17.9 n.s. 17.6
Virological nonresponse 9.1 10.4 * 9.7 11.2 13.1 ** 12.1
Poor tolerability 5.1 3.1 *** 4.2 6.3 4.0 *** 5.2
Other reasons 10.2 14.9 *** 12.5 1.5 2.5 *** 2.0
Death 0.1 0.3 ** 0.2 0.1 0.3 ** 0.2
Mean treatment duration (weeks) 33.3 32.8 n.s. 33.1 35.0 35.0 n.s. 35.0
Mean ribavirin dosage (mg/kg) 11.1 11.8 *** 11.5 11.6 12.5 *** 12.0
(Continued)
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The overall SVR rates were significantly higher in the later than in the earlier period (64.3%
versus 61.2%; p = 0.008). The SVR rates in patients with genotype 1 infection were 51.9% in the
earlier years versus 56.3% in the later years (p = 0.0057). For genotype 3 infected patients SVR
rates showed no statistical difference (80.5% versus 81.0%, p = 0.8070). For genotype 2 infected
patients, SVR rates were 71.4% in the earlier years versus 75.5% in the later years (p = 0.5091).
Improved SVR rates were observed throughout all relevant subgroups, namely those with
favorable and those with unfavorable baseline characteristics. Patients below the age of 45 had
response rates of 71.8% in 2003–2007 and 75.2% in 2008–2011, respectively (p = 0.0296), and
patients aged 45 or older had response rates of 47.1% in 2003–2007 and 50.8% in 2008–2011,
respectively (p = 0.0618). SVR rates in patients with low viral load was 70.2% and 72.3%,
respectively, while patients with high viral load showed response rates of 54.0% vs. 58.0%,
respectively (p = 0.0179). In patients with normal baseline gamma-GT, response rates were
72.0% in the earlier years and 74.6 in the later years (p = 0.0884), whereas patients with elevated
gamma-GT showed response rates of 48.3% in 2003–2007 and of 52.1% in 2008–2011
(p = 0.0469).
By univariate testing, factors other than the treatment period were significant predictors of
treatment success. The HCV genotype (p<0.0001) as well as viral load (p<0.0001) were signifi-
cantly associated with SVR as were patient age (p<0.0001) and possible route of infection
(p<0.0001). Presence of concomitant disease (p = 0.002), substitution for opioid abuse
(p<0.0001), and elevated gamma-GT (p = 0.0001) as well as higher APRI score (p<0.0001)
had a negative impact on treatment outcome. The duration of treatment was inversely associ-
ated with success rates (p<0.0001). This apparent paradox is explained by the selection of
patients with unfavorable baseline characteristics such as higher age, BMI, GGT, proportion of
patients with high baseline viral load and on-treatment parameters for longer treatment dura-
tion (data not shown). For example, the proportion of patients with APRI score> 1.5 was 5.7%
in patients with shorter treatment duration compared with 10.3% in patients with longer treat-
ment duration, which may also contribute to this explanation. The dose of ribavirin showed a
weak, borderline statistically significant, association with treatment response (p = 0.046).
Table 1. (Continued)
ITT PP
2003–2007 2008–2011 p-value total 2003–2007 2008–2011 p-value total
Genotype 1 10.9 11.2 ** 11.1 11.3 11.9 *** 11.6
Genotype 2 11.3 13.0 *** 12.0 11.8 13.5 *** 12.6
Genotype 3 11.5 12.7 *** 12.1 12.2 13.5 *** 12.8
Genotype 4 10.5 10.6 n.s. 10.5 10.8 11.2 n.s. 11.0
Genotype 5 11.3 11.4 n.s. 11.3 11.6 13.0 n.s. 12.0
Genotype 6 12.3 13.2 n.s. 12.6 12.9 13.8 n.s. 13.2
†Data on ethnicity were not collected in 2003. Hence, no data on ethnicity are available for the very early era of HCV treatment. There is no indication that
the composition of ethnicity in 2003 is different from that in the following years (2004–2007)
‡ multiple answers possible
APRI, aspartate aminotransferase (AST) platelet ratio index; BMI, body mass index; GGT, gamma-glutamyl transferase; n.s., not signiﬁcant; RVR, rapid
virological response; SVR, sustained virological response
*p < 0.05;
** p < 0.01,
*** p < 0.001
doi:10.1371/journal.pone.0134839.t001
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Table 2. Baseline demographics, virological responses, treatment discontinuations as well as treatment duration andmean ribavirin dose in two
periods of 2003–2007 and 2008–2011 in the matched pairs PP andmatched pairs PP completer population.
Matched pairs PP Matched pairs PP completers
2003–2007 2008–2011 p-value total 2003–2007 2008–2011 p-value total
Number of patients (n) 2997 2997 5994 2439 2475 5994
Age (Yrs, mean) 42.4 42.6 n.s. 42.5 41.3 41.6 n.s. 42.5
Gender (male, %) 61.0 61.0 n.s. 61.0 61.5 61.1 n.s. 61.0
BMI (kg/m2, mean) 25.2 25.6 *** 25.4 25.1 25.5 ** 25.4
Ethnicity, Caucasian (%; adjusted by unknown)† 76.0 96.9 n.s. 86.5 76.7 96.9 n.s. 86.5
APRI Score (%) n.s. n.s.
< 0.5 46.6 46.6 46.6 48.8 48.7 46.6
0.5-< = 1.5 43.8 43.8 43.8 44.2 44.1 43.8
1.5-< = 2 2.4 2.4 2.4 2.0 1.9 2.4
>2 7.2 7.2 7.2 4.9 5.3 7.2
Baseline GGT (IU/ml, mean) 80 90 n.s. 85 70 74 n.s. 85
Route of infection (%): n.s. n.s.
Transfusion/blood products 12.1 12.1 12.1 11.1 11.1 12.1
Intravenous drug abuse 38.5 38.5 38.5 41.0 41.3 38.5
Other (unknown) 49.4 49.4 49.4 47.9 47.6 49.4
Concomitant diseases (%): 49.6 49.6 n.s. 49.6 48.6 47.8 n.s. 49.6
Psychiatric 9.5 12.7 *** 11.1 9.2 12.4 *** 11.1
Cardiovascular 8.2 8.8 n.s. 8.5 7.3 7.5 n.s. 8.5
Diabetes 4.1 3.9 n.s. 4.0 3.2 3.1 n.s. 4.0
Pulmonary 3.3 2.7 n.s. 3.0 3.0 2.8 n.s. 3.0
Former iv drug abuse 17.5 20.0 * 18.7 18.9 21.4 * 18.7
Opioid substitution treatment 8.6 8.6 n.s. 8.6 9.4 9.2 n.s. 8.6
Genotype (%): n.s. n.s.
1 64.9 64.9 64.9 59.7 59.8 64.9
2 4.9 4.9 4.9 5.7 5.7 4.9
3 28.7 28.7 28.7 33.3 33.2 28.7
4 1.4 1.4 1.4 1.3 1.3 1.4
High baseline viral load (> 470,000 IU/ml, %) 55.8 55.8 n.s. 55.8 53.9 53.3 n.s. 55.8
RVR (%) 40.8 40.2 n.s. 40.4 48.4 46.4 n.s. 40.4
SVR total (%) 61.2 64.3 * 62.7 74.3 77.9 ** 62.7
SVR genotype 1 (%) 51.9 56.3 ** 54.1 68.5 73.9 ** 54.1
SVR genotype 2 (%) 71.4 75.5 n.s. 73.5 74.8 79.3 n.s. 73.5
SVR genotype 3 (%) 80.5 81.0 n.s. 80.7 84.4 84.8 n.s. 80.7
SVR genotype 4 (%) 58.1 55.8 n.s. 57.0 77.4 75.0 n.s. 57.0
Treatment discontinuation (%)‡ 17.8 17.4 n.s. 17.6 0.0 0.0 17.6
Virological nonresponse 11.8 13.0 n.s. 12.4 12.4
Poor tolerability 6.3 3.6 *** 4.9 4.9
Other reasons 1.5 2.4 * 2.0 2.0
Death 0.0 0.3 ** 0.2 0.2
Mean treatment duration (weeks) 35.8 35.8 n.s. 35.8 39.0 38.6 n.s. 35.8
Mean ribavirin dosage (mg/kg) 11.6 12.6 *** 12.1 12.8 13.8 *** 12.1
Genotype 1 11.4 12.1 *** 11.7 13.2 13.8 *** 11.7
Genotype 2 11.5 13.3 ** 12.4 11.8 13.4 ** 12.4
Genotype 3 12.0 13.5 *** 12.8 12.2 13.7 *** 12.8
(Continued)
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Effect of individualization of treatment duration on treatment efficacy. To evaluate the
effect of individualization of treatment regimens between the earlier and the later period, we
analyzed the MP-PP completer cohort regarding planned treatment durations according to
genotype. The mean treatment duration was 35.8 weeks for all patients in both periods. How-
ever, treatment duration was significantly more heterogeneous in the later period. In genotype
1/4 patients, the standard treatment duration of 48 weeks was chosen in 81.2% of patients who
completed the treatment in the years 2003–2007, while only 64.6% of patients who completed
the treatment were treated for 48 weeks in 2008–2011. Treatment was abbreviated in more
patients in the later than in the earlier period (19.2% versus 9.3% of patients who completed
the treatment; Fig 2). Likewise, treatment extension was more frequent in the later than in the
earlier period (16.1% versus 9.5% of patients who completed the treatment). The same effect
was observed in genotype 2/3 patients, in whom the standard treatment duration is 24 weeks.
87.2% of patients who completed the treatment were treated for 24 weeks in the years 2003–
2007 while only 75.6% of patients who completed the treatment were treated for 24 weeks in
the years 2008–2011. In contrast, more patients were treated for a shorter duration in the later
period (10.0% of patients who completed the treatment) than in the earlier period (3.0% of
patients who completed the treatment; Fig 3). Again, treatment was also extended in more
patients in the later period. In 2008–2011, treatment durations beyond 28 weeks were observed
in 14.4% of patients who completed the treatment while only 9.8% of patients who completed
the treatment were treated longer in the years 2003–2007.
Of the patients in the MP-PP completer cohort with favorable predictive factors
(APRI< 0.5, low baseline viral load (<800.000 IU/ml), RVR) who qualified for the shortening
of treatment in principle, the percentage of patients who actually received abbreviated treat-
ment courses increased between the earlier and the later period. 27.7% of genotype 1/4 infected
patients received treatment for less than 44 weeks in the earlier period compared to 59.3% in
the later period. Likewise, the percentage of eligible patients with genotype 2/3 infection receiv-
ing less than 20 weeks of therapy rose from 4.8% to 25.3%.
Effect of individualization of ribavirin dosing on treatment efficacy. We analyzed
whether prescription of ribavirin followed a more individualized regimen in the later period
than in the earlier period, thus reflecting dosing according to actual weight rather than the cate-
gories put forward in the prescription information. The mean ribavirin dose was 11.6 mg/kg in
the 2003–2007 period and 12.6 mg/kg in the 2008–2011 period in the MP-PP cohort (p<0.001,
OR = 1.051, CI 95%:1.035–1.067). In patients achieving an SVR, mean ribavirin doses were
Table 2. (Continued)
Matched pairs PP Matched pairs PP completers
2003–2007 2008–2011 p-value total 2003–2007 2008–2011 p-value total
Genotype 4 10.1 11.8 n.s 11.0 12.2 13.6 n.s. 11.0
†Data on ethnicity were not collected in 2003. Hence, no data on ethnicity are available for the very early era of HCV treatment. There is no indication that
the composition of ethnicity in 2003 is different from that in the following years (2004–2007)
‡ multiple answers possible
APRI, aspartate aminotransferase (AST) platelet ratio index; BMI, body mass index; GGT, gamma-glutamyl transferase; n.s., not signiﬁcant; RVR, rapid
virological response; SVR, sustained virological response
*p < 0.05;
** p < 0.01,
*** p < 0.001
doi:10.1371/journal.pone.0134839.t002
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Fig 2. Comparison of treatment duration in patients infected with genotype 1/4 between 2003–2007
and 2008–2011 period.MP, matched pairs; PP, per protocol.
doi:10.1371/journal.pone.0134839.g002
Fig 3. Comparison of treatment duration in patients infected with genotype 2/3 between 2003–2007
and 2008–2011 period.MP, matched pairs; PP, per protocol.
doi:10.1371/journal.pone.0134839.g003
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12.7 mg/kg and 13.7 mg/kg in the earlier and the later period, respectively. The percentage of
patients receiving a ribavirin dose exceeding 13.2 mg/kg was 44.5% in the earlier period and
56.0% in the later period. The latter analysis was restricted to patients who reached a planned
treatment stop since cumulative ribavirin doses are not meaningful when treatment was
stopped prematurely.
Multivariate analysis. Multivariate analysis was performed in the MP-PP completer
cohort. SVR rates between the two treatment periods remained significantly different
(p = 0.002, OR = 1.254, CI 95%:1.089–1.444). Virus genotype 3 vs. 1 (p<0.0001, OR = 1.851,
CI 95%: 1.549–2.212) and low baseline viral load (p<0.0001, OR = 1.567, CI 95%: 1.355–1.813)
predicted treatment outcome. Younger patient age (p<0.0001, OR = 2.063, CI 95%: 1.773–
2.399), normal gamma-GT values (p<0.0001, OR = 1.528, CI 95%: 1.312–1.779), and female
gender (p<0.010, OR = 1.238, CI 95%: 1.065–1.440) as well as lower APRI score (0.028,
OR = 1.533, CI 95%: 1.128–2.084) and higher ribavirin dose (p = 0.032, OR = 1.024, CI: 0.861–
1.219) were significantly associated with success rates. Treatment duration remained inversely
correlated with treatment outcomes, with lower SVR rates in patients treated for longer
durations.
Discussion
Treatment of chronic HCV infection with pegIFN alfa and ribavirin has been the standard of
care for many years [5]. Individualization of this treatment increased outcomes in many ran-
domized controlled trials and allowed patients to shorten treatment without compromising
efficacy, thus saving costs and sparing the patients side effects [12]. However, it is unknown
whether treatment individualization was implemented by the majority of physicians who
treated patients in office-based practices, and whether individualization of treatment conferred
any benefit regarding treatment outcomes in the real life setting.
The large noninterventional cohort study presented here shows that individualization of
HCV treatment was indeed more common in the 2008–2011 period than in the 2003–2007
period, i.e. after individualization was included as a recommendation into national and inter-
national treatment guidelines [30, 32]. In the present study treatment durations other than 24
weeks for genotypes 2/3 and other than 48 weeks for genotypes 1/4 as well as the dosing of riba-
virin were analyzed as indicators for individualization between the two treatment periods.
However, SVR rates in both treatment periods did not differ significantly (overall SVR rates
were 62.0% and 63.7%, respectively). The effect on treatment outcomes was most likely con-
founded by the fact that treatment had been extended to sicker patients in the later period.
Indeed, the proportion of patients with concomitant diseases was 44.3% in the earlier period as
compared to 57.1% in the later period.
To allow analysis despite this confounding factor, we performed a matched-pair analysis, in
which patients were matched for baseline factors including To allow analysis despite this con-
founding factor, we performed a matched-pair analysis, in which patients were matched for the
following baseline factors known to influence treatment outcome: age (range of 5 years), HCV
genotype, baseline viral load (low or high viral load with best cut-off of 470.000 IE/ml),
APRI-Score (< 0.5, 0.5–< = 1.5, 1.5–< = 2,> 2), possible route of infection (intravenous drug
abuse, blood or blood products, unknown), presence or absence of concomitant diseases, base-
line gamma-GT (within normal range versus elevated), and substitution for intravenous drug
abuse. (10). Strikingly, after matching for these confounders, SVR rates in the 2008–2011
period were significantly higher than in the earlier period. SVR rates improved in both easier to
treat as well as more difficult to treat patient populations. This finding suggests that physicians
became better acquainted with treatment regimens and the management of side effects,
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allowing more patients to remain on treatment or uphold the assigned doses of pegIFN alfa
and ribavirin.
As an indicator for individualization, the number of patients who received their treatment
for durations other than 24 weeks for genotypes 2/3 and 48 weeks for genotypes 1/4 (reviewed
in [12]) was higher in the 2008–2011 period than in the 2003–2007 period. More patients were
treated with an abbreviated regimen of 24 weeks in genotype 1/4 infection and 16 weeks in
genotype 2/3 patients without compromising SVR rates. While 81.2% of patients infected with
HCV genotypes 1/4 in the earlier period received treatment for the standard duration of 48
weeks, this number dropped to 64.6% in the later period. The same difference was observed in
patients with genotype 2/3 infection, in which 87.2% and 75.6% of patients received the stan-
dard treatment of 24 weeks in the earlier and later period, respectively. The difference was due
to both, higher numbers of patients receiving abbreviated regimens in the later than in the ear-
lier years (19.2% versus 9.3% in patients with genotype 1/4 infection and 10.0% versus 3.0% in
patients with genotype 2/3 infection) and higher numbers of patients receiving extended treat-
ments (16.1% versus 9.5% in patients with genotype 1/4 infection and 14.4% versus 9.8% in
patients with genotype 2/3 infection).
When only those genotype 1/4 patients who were eligible for treatment abbreviation in prin-
ciple were considered, the proportion of patients who indeed received less than 48 weeks of
therapy doubled in the later period from 27.7% to 59.3%. While this increase is substantial,
individualization of treatment duration was forgone in approximately 40% of eligible patients.
A previous prospective clinical trial demonstrated that 29% of treatment naive HCV patients
infected with genotype 1/4 were eligible for abbreviation of treatment duration, likewise indi-
cating that individualization of treatment durations was not yet commonplace in daily practice
in Germany [18].
The second indicator for treatment individualization which could contribute to better SVR
rates in the later period is the adjustment of ribavirin dosing to the actual body weight rather
than to the categories of body weight suggested in the label, as proposed in earlier clinical trials
[33, 34]. Despite the label, which sets the ribavirin dose at 1200 mg for patients weighing 75 kg
or more and at 1000 mg in patients weighing less than 75 kg in genotype 1 and 4 infected
patients and at 800 mg flat for all patients infected with genotypes 2 or 3, recent data suggests
that this dose is insufficient for some patients, especially those which receive less than 13 mg/
kg of ribavirin in genotypes 1/4 and less than 10 mg/kg in genotypes 2/3 [33]. We observed
that higher ribavirin doses were prescribed in the later than in the earlier period. The mean
ribavirin dose per kg was 1 mg higher in the later than in the earlier period in all patients as
well as in patients achieving an SVR. However, the ribavirin dose was higher to a similar extent
in patients not achieving an SVR, suggesting that increased ribavirin dosing was at least not the
only factor responsible for the improvement of SVR rates. The multivariate analysis of factors
associated with SVR in the MP-PP completer cohort showed that treatment in the later period,
younger age, female gender, HCV genotype non-1/4, lower baseline viral load, lower APRI
score, normal gamma-GT, longer treatment duration, and higher ribavirin dosing were inde-
pendently associated with treatment success. These data underline the importance of treatment
individualization, which adds to well-established predictors in the real world setting.
Are the results from the present study still relevant in the beginning era of interferon-free
treatment regimens [35]? While a relatively liberal access to DAAs is anticipated in western
countries, many parts of the world will not easily implement interferon-free treatment regi-
mens given their excessive costs [36]. Therefore, pegIFN alfa will possibly remain a part of the
standard of care until access strategies for DAAs in lower-income countries have been initiated.
Treatment individualization is cost-effective [37], and the factors identified here in a large
cohort of patients treated with pegIFN alfa-2a and ribavirin may still apply to patients treated
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with triple regimens, although individualization of treatment durations is largely offset by the
mandatory response-guided treatment approaches in boceprevir- and telaprevir-based triple
treatment [38] and by the fixed treatment durations mandated in simeprevir- and sofosbuvir-
based triple treatment [39, 40].
This study was an observational study, which gave the participating physicians liberty to
decide on treatment duration as well as on dosing. Naturally, data from an observational study
are more susceptible to bias resulting from poorer quality of data. On the contrary, only a real-
life study allows the observation of treatment effects in a population that is not heavily selected
for homogeneity and excludes problematic patients, as is typically the case in randomized con-
trolled studies. We therefore believe that the current study is a valuable addition to the data
generated in randomized controlled studies by providing data from a sample size unaffordable
in controlled studies and including patients with unfavorable baseline factors, which may be
deemed unsuitable for participation in controlled studies. The limitation of our study is the
absence of a mandatory treatment protocol, leaving space for deviation from the treatment reg-
imens recommended in guidelines. However, we believe that the very large sample size, which
to our knowledge is the largest in any observational study in hepatitis C treatment, levels the
potential bias and is the biggest asset of this study.
In summary, our data show that individualization of HCV therapy was cautiously imple-
mented in daily practice among patients treated for chronic hepatitis C infection in Germany.
Indicators for individualization included heterogenous treatment durations as well as higher
ribavirin doses. Treatment individualization resulted in higher SVR rates comparable to those
observed in randomized controlled trials.
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